The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HIND | -99.15% | -100% | -92.41% | -72% |
| S&P | +15.66% | +86.6% | +13.29% | +7% |
ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, the Obalon Balloon System, and the Diabetes Bloc-Stim Neuromodulation device. The firm sells the Lap-Band worldwide and is managed in the following geographical regions: United States, Australia, Europe, and the Rest of World. The company was founded in December 2002 and is headquartered in Irvine, CA.
No news articles found for Vyome.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $34.63K | -98.5% |
| Gross Profit | $15.24K | -98.9% |
| Gross Margin | 44.02% | -18.8% |
| Market Cap | $3.49M | -12.4% |
| Market Cap / Employee | $193.77K | 0.0% |
| Employees | 18 | -41.9% |
| Net Income | -$8,595.30K | -443.7% |
| EBITDA | -$865.97K | 50.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.71M | 577.0% |
| Accounts Receivable | $23.00K | -98.3% |
| Inventory | 0 | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.15K | -89.4% |
| Short Term Debt | $30.46K | -73.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -179.31% | -74.2% |
| Return On Invested Capital | 340.10% | 701.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $4.34M | 1496.3% |
| Operating Free Cash Flow | $4.34M | 1496.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -12.87 | 0.98 | 1.10 | 0.58 | -78.23% |
| Price to Sales | 0.41 | 0.10 | 0.44 | 3.41 | 869.57% |
| Price to Tangible Book Value | 211.36 | 17.08 | 1.06 | 0.58 | -99.38% |
| Enterprise Value to EBITDA | -5.38 | 0.97 | 0.62 | -11.56 | 812.51% |
| Return on Equity | -222.5% | -120.2% | -101.5% | -565.2% | 82.74% |
| Total Debt | $967.00K | $130.00K | $104.00K | $38.61K | -79.79% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
